Side Area Logo
Welcome to unde omnis iste natus error sit voluptatem accusantium
Keep conected



Windtree Therapeutics is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Windtree Therapeutics' technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies.  Windtree Therapeutics' strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Windtree Therapeutics believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy but are currently not treated.

Recent News
Jan 2, 2019

Windtree Therapeutics, Inc. (OTCQB: WINT), will host a conference call and webcast for investors on Thursday, January 3, 2019 at 8:00 a.m. EST. This call will be the first since the Company...

Dec 21, 2018

Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, and CVie Investments Limited (CVie),...

Dec 10, 2018

Windtree Therapeutics, Inc. (OTCQB: WINT) today announced that data from the AEROSURF® phase 2 clinical program in premature infants with respiratory distress syndrome (RDS) was presented at the...